US Patent 6,001,861: Scope, Claims, Expiration, and Pramipexole Patent Landscape

US Patent 6,001,861 protected the use of pramipexole for restless legs syndrome (RLS). Its claims covered the active compound, the (-)-enantiomer, specified salts, and daily doses ranging from 0.01 to 10 mg, including the narrower 0.75 to 4.5 mg range. The patent was a method-of-use patent, not a compound or formulation patent. Its US patent term expired on May 7, 2016, subject to any applicable pediatric exclusivity period. It no longer creates a patent barrier to generic pramipexole for RLS.

What does US Patent 6,001,861 protect?

US 6,001,861 covers administration of pramipexole to treat RLS. The patent does not claim the chemical discovery of pramipexole itself. It claims the therapeutic application of the compound in RLS patients.

Item	Details
Patent	US 6,001,861
Title	Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole for the treatment of restless legs syndrome
Patent holder	Boehringer Ingelheim-affiliated entities
Active ingredient	Pramipexole
Chemical form	Pramipexole, its (-)-enantiomer, pharmacologically acceptable salts, dihydrochloride and dihydrochloride monohydrate
Therapeutic use	Treatment of restless legs syndrome
Filing route	PCT-derived US national-stage application
Relevant international priority date	May 7, 1996
US patent issue date	December 14, 1999
US term expiration	May 7, 2016
Patent category	Method of treatment
Current blocking effect	None after expiration

The patent is directed to pramipexole, commercially marketed in the United States as Mirapex and later Mirapex ER. Pramipexole is a dopamine D2/D3 receptor agonist.

How broad are the claims of US 6,001,861?

The claims have broad therapeutic language but materially different legal coverage.

Claim 1: compound, enantiomer, and salts

Claim 1 covers:

2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole;
its (-)-enantiomer; and
pharmacologically acceptable salts.

This claim is broader than claim 2 because it is not limited expressly to the name "pramipexole" or to the dihydrochloride forms. The chemical description is intended to capture pramipexole and related salt forms used therapeutically.

The phrase "an effective amount" is a conventional method-of-treatment limitation. It requires a dose sufficient to produce a therapeutic effect, but it does not impose a single fixed dose. The phrase "a patient suffering from or susceptible to" also extends beyond patients with established symptoms. It may reach prophylactic or risk-based treatment, although the practical scope depends on the evidence supporting the patient's susceptibility and the treatment purpose.

Claim 2: pramipexole and specified salts

Claim 2 narrows the subject matter to:

pramipexole;
pramipexole dihydrochloride; and
pramipexole dihydrochloride monohydrate.

This is the principal commercial claim because pramipexole dihydrochloride monohydrate is the pharmaceutical form historically used in Mirapex tablets.

Claim 2 is still broad with respect to:

tablet strength;
dosing schedule;
immediate-release or other delivery format;
treatment duration; and
patient age, unless limited by the specification or regulatory labeling.

The claim requires treatment of RLS. It does not cover use of pramipexole for Parkinson's disease, which was an earlier and separately approved indication.

Claim 3: broad dose range

Claim 3 limits claim 2 to approximately 0.01 to 10.0 mg per day.

The word "about" creates tolerance around the numerical endpoints. The claim is not limited to a specific strength or dosing frequency. A once-daily, twice-daily, or divided-dose regimen could potentially fall within the claim if the total daily amount is within the claimed range.

Claim 4: commercially relevant dose range

Claim 4 narrows claim 2 to approximately 0.75 to 4.5 mg per day.

This range corresponds more closely to the historical therapeutic dosing range associated with pramipexole treatment. It is narrower than claim 3 and would be infringed only by a regimen falling within, or sufficiently close to, that range.

Claim	Scope	Commercial significance
1	RLS treatment using the chemical entity, (-)-enantiomer or acceptable salts	Broadest chemical and therapeutic claim
2	RLS treatment using pramipexole or specified dihydrochloride forms	Core product-use claim
3	Claim 2 with approximately 0.01-10.0 mg/day	Broad dosing limitation
4	Claim 2 with approximately 0.75-4.5 mg/day	Narrower commercial dosing limitation

What patent type is US 6,001,861?

US 6,001,861 is a second medical-use patent. It does not claim:

the basic pramipexole molecule as a composition of matter;
a specific tablet formulation;
a sustained-release matrix;
a manufacturing process;
a dosage form as such; or
a method of treating Parkinson's disease.

Its value arose from a new indication for an existing dopamine agonist. That distinction matters because the underlying compound patent and the RLS use patent had different expiration dates.

When did pramipexole compound protection expire?

The original pramipexole compound protection predates US 6,001,861 and expired earlier than the RLS patent.

The relevant commercial sequence was:

Event	Approximate date
Pramipexole compound protection issued	Early 1990s
Mirapex approved for Parkinson's disease	1997
US 6,001,861 issued	December 14, 1999
Mirapex approved for RLS	2006
US 6,001,861 term expiration	May 7, 2016
Potential pediatric exclusivity extension	Up to six additional months, if applicable

The distinction between compound and indication protection allowed generic manufacturers to challenge pramipexole for Parkinson's disease before the RLS patent expired. For RLS, the commercial risk depended on the generic applicant's labeling strategy and whether its proposed label included or carved out the patented indication.

What was the FDA and Orange Book status of US 6,001,861?

The FDA approved Mirapex for Parkinson's disease in 1997 and later approved it for moderate-to-severe primary RLS in 2006. The RLS approval created the regulatory setting in which US 6,001,861 became relevant to abbreviated new drug applications (ANDAs).

The patent was listed in the FDA Orange Book in connection with pramipexole products and the RLS method of use. An Orange Book listing can require an ANDA applicant to submit one of the statutory patent certifications:

Paragraph I: no patent information has been submitted;
Paragraph II: the patent has expired;
Paragraph III: the applicant will wait until patent expiration; or
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

After May 7, 2016, the appropriate certification for the expired patent was generally Paragraph II, subject to the product-specific listing and any applicable exclusivity.

Orange Book listing did not extend the patent term. It also did not convert the method-of-use patent into a patent on all pramipexole products.

Which companies challenged pramipexole patent protection?

Generic manufacturers challenged pramipexole protection through ANDA filings as the compound and method-of-use patents approached expiration. The most important legal route was a Paragraph IV challenge or a label-carveout strategy for products directed to non-RLS uses.

For a generic applicant, the central distinction was:

Proposed generic label	Exposure under US 6,001,861
Parkinson's disease only	Lower exposure to the RLS method claims
RLS and Parkinson's disease	Direct method-of-use exposure
RLS indication carved out	Potentially reduced infringement risk
Broad label reproducing Mirapex RLS language	Highest exposure
Product marketed after May 7, 2016	No remaining infringement liability under the expired patent

The available claim set does not itself establish which specific manufacturer prevailed in a particular ANDA dispute. Litigation conclusions must be tied to docket records, settlement agreements, and final judgments rather than inferred from the patent claims.

What patent litigation affected US 6,001,861?

The central litigation issue for this patent class was whether an ANDA applicant could market pramipexole without infringing a patented RLS indication. The relevant legal questions included:

Whether the proposed generic label instructed treatment of RLS.
Whether the label carved out the patented indication.
Whether the claims were valid over earlier dopamine agonist and RLS disclosures.
Whether the asserted dose ranges were anticipated or obvious.
Whether the claimed RLS use was adequately supported by the patent disclosure.
Whether the patent remained enforceable when the generic product launched.

After expiration, infringement litigation under US 6,001,861 became moot as a prospective market-exclusion issue. Any historical litigation could still matter for damages, settlement interpretation, or launch timing, but the patent no longer supports an injunction against current generic RLS products.

How strong was the patent estate for pramipexole?

The estate was commercially strong during the protected period but limited in structure.

Strengths

It covered the clinically important RLS indication.
It expressly named pramipexole and its principal dihydrochloride forms.
It included broad and narrower dose ranges.
It applied to treatment of patients suffering from or susceptible to RLS.
It could delay an ANDA applicant that sought an RLS label without a successful challenge or carveout.

Limitations

It was not a compound patent.
It did not prevent manufacture of pramipexole for unpatented indications after compound protection expired.
It did not independently protect every formulation or extended-release product.
Method-of-use claims depend heavily on the wording of the proposed label and actual use.
The patent had a fixed expiration date in 2016.
The claims could have faced validity challenges based on obviousness, anticipation, written description, enablement, or claim construction.

The estate's commercial leverage therefore depended on regulatory labeling and market behavior more than on control of the underlying molecule.

What formulation patents protected Mirapex and Mirapex ER?

US 6,001,861 should be separated from formulation and extended-release protection.

Immediate-release Mirapex tablets primarily relied on pramipexole's active-ingredient and indication protection. Extended-release products such as Mirapex ER could involve separate patent families directed to controlled-release delivery, dosage forms, or manufacturing methods. Those patents were not automatically covered by US 6,001,861.

A competitor could therefore face different risks depending on its product:

Product type	Relevance of US 6,001,861	Other potential IP
Immediate-release pramipexole	Direct RLS method-of-use relevance	Compound and formulation patents
Pramipexole dihydrochloride tablets	Directly named in claim 2	Tablet and manufacturing patents
Extended-release pramipexole	RLS claim may apply to the use	Controlled-release formulation patents
Non-RLS pramipexole	Generally outside the RLS claims	Product-specific patents
Alternative dopamine agonist	Outside the chemical limitations	Its own compound and indication patents

Are biosimilar risks relevant to pramipexole?

No. Pramipexole is a chemically synthesized small molecule, not a biologic. The relevant FDA pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.

The competitive risks are therefore:

ANDA approval;
Paragraph IV litigation;
section viii statement or RLS indication carveout;
generic labeling disputes; and
formulation or extended-release patents.

Biosimilar interchangeability, reference-product exclusivity, and biologic manufacturing comparability are not material issues for US 6,001,861.

What generic launch scenarios existed?

Three launch scenarios were commercially relevant.

Early launch after a successful challenge

A generic company could launch before expiration if it prevailed in Paragraph IV litigation or obtained a settlement permitting early entry. The risk would include damages, injunction exposure, and possible invalidity findings.

Carved-out launch

A manufacturer could seek approval for a label excluding RLS while retaining Parkinson's disease use. This approach could support earlier market entry but would limit the approved indication and create risks if the product were marketed or promoted for RLS.

Post-expiration launch

After May 7, 2016, generic manufacturers could pursue RLS labeling without facing the expired patent. This was the lowest-risk route under US 6,001,861.

What licensing and geographic issues affected the patent?

The patent was a US right. It did not block commercialization in Europe, Japan, Canada, or other territories. Foreign counterparts required separate analysis of:

national validation;
local patent term;
supplementary protection certificates;
regulatory exclusivity;
national claim amendments;
opposition or revocation proceedings; and
local settlements.

Boehringer Ingelheim's commercial rights and licensing arrangements for pramipexole could differ by territory. A US Orange Book listing did not establish ownership or enforceability of foreign counterparts.

The patent also did not automatically control manufacturing outside the United States. A foreign manufacturer could produce pramipexole for export, subject to the law of the manufacturing country, destination-country rights, and possible US import or offer-for-sale issues.

What is the current commercial impact of US 6,001,861?

The patent has no current exclusionary value because its US term expired in 2016. Current pramipexole competition is governed by:

generic ANDA approvals;
any surviving formulation or extended-release patents;
manufacturing economics;
supply reliability;
approved labeling;
reimbursement and pharmacy substitution; and
brand residual demand.

The principal historical revenue exposure was Mirapex RLS sales during the period between the 2006 RLS approval and patent expiration. Once generic immediate-release pramipexole entered, price erosion and generic substitution reduced the value of the branded indication patent.

Key Takeaways

US 6,001,861 is a method-of-use patent for treating RLS with pramipexole.
Claim 1 is the broadest claim and covers the compound, its (-)-enantiomer, and acceptable salts.
Claim 2 specifically covers pramipexole and its dihydrochloride forms.
Claims 3 and 4 limit the method to daily dose ranges of approximately 0.01-10.0 mg and 0.75-4.5 mg, respectively.
The patent does not protect the pramipexole molecule as such.
It does not claim a formulation, extended-release delivery system, or manufacturing process.
The US patent term expired on May 7, 2016, subject to any applicable pediatric exclusivity.
Pramipexole is a small molecule, so biosimilar law is irrelevant.
Current generic entry is not blocked by US 6,001,861.
Any remaining pramipexole IP risk must be evaluated separately for formulation, extended-release, manufacturing, and foreign patents.

FAQs About US Patent 6,001,861 and Pramipexole

Does US 6,001,861 cover pramipexole for Parkinson's disease?

No. The asserted claims are limited to treatment of restless legs syndrome. They do not claim treatment of Parkinson's disease.

Can a generic company sell pramipexole for RLS today?

Yes, the patent expired in 2016. A generic applicant must still satisfy FDA approval requirements and address any separate surviving patents, but US 6,001,861 no longer blocks RLS marketing.

Does claim 4 cover a 0.75 mg pramipexole dose?

Potentially, subject to claim construction of the term "about." The claimed range is approximately 0.75 to 4.5 mg per day, so a 0.75 mg daily regimen is at the stated lower endpoint.

Is pramipexole dihydrochloride monohydrate a separate active ingredient?

No. It is a salt and hydrate form of pramipexole used for pharmaceutical formulation. Claim 2 expressly identifies the dihydrochloride and dihydrochloride monohydrate forms.

Does expiration of US 6,001,861 eliminate all pramipexole patent risk?

No. It eliminates the RLS method-of-use patent barrier, but separate formulation, extended-release, manufacturing, or foreign patents could have different terms and claim scopes.

References

U.S. Patent and Trademark Office. (1999). U.S. Patent No. 6,001,861: Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole for the treatment of restless legs syndrome.
U.S. Food and Drug Administration. (2006). Mirapex prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
U.S. Food and Drug Administration. (2024). Approved drug product labeling and patent certification requirements under the Hatch-Waxman Amendments.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and exclusivity.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	281165	⤷ Start Trial
Australia	6016898	⤷ Start Trial
Australia	723119	⤷ Start Trial
Bulgaria	103543	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,001,861

Summary for Patent: 6,001,861